Takayuki Iwaki

Dr. Takayuki Iwaki

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2012 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
TITakayuki Iwaki
Takayuki Iwaki
TUTetsumei Urano
Tetsumei Urano
KUKazuo Umemura
Kazuo Umemura

12 April 2011 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
PDF file
TITakayuki Iwaki
Takayuki Iwaki
ATA. Tanaka
A. Tanaka
YMY. Miyawaki
Y. Miyawaki
ASA. Suzuki
A. Suzuki
TKT. Kobayashi
T. Kobayashi
NKN. Kanayama
N. Kanayama
Summary. Background: Plasminogen activator inhibitor‐1 (PAI‐1) is the primary physiological regulator of urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA) activity. A number of studies have shown that elevated levels of PAI‐1 are related to pathological states such as an increased risk of arterial thrombotic events and a poor prognosis for cancer patients; however, there are few reports about PAI‐1 deficiency in humans because the disorder is very rare. Objective: To understand the in vivo impact of a complete PAI‐1 deficiency, Serpine1−/− mice were generated; a number of in vivo studies have been conducted to elucidate the function of PAI‐1 using Serpine1−/− mice. The phenotypes demonstrated in Serpine1−/− mice, however, were quite different from those in humans. Therefore, it is necessary to find out and analyze SERPINE1 deficiency in humans. Patient and methods: The patient is a 47‐year‐old woman who has had multiple episodes of major bleeding. Although most of the patient’s blood coagulation factors were functionally normal, her PAI‐1 antigen levels were undetectable. Therefore, DNA sequencing of the SERPINE1 gene were analyzed. Results: The proband had a homozygous 1‐bp duplication (C) at exon 3 (c.356dupC; p.Ile120AspfsX42). Both wild‐type PAI‐1 (42.7 kDa) and mutated (Mut) PAI‐1 (14.7 kDa) were expressed in COS‐1 cells, although the level of Mut PAI‐1 expressed in the cell lysates was much lower. Wild‐type PAI‐1 was observed in the culture supernatant, whereas no Mut PAI‐1 was detected in the supernatant. Conclusions: Considering the results of the present study, the translation of mouse studies to humans must be performed with great care.

1 June 2020 in Protein Expression and Purification
Verified
Journal Article
Closed access
TITakayuki Iwaki
Takayuki Iwaki
KHKimiko Hara
Kimiko Hara
KUKazuo Umemura
Kazuo Umemura

13 November 2017 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
KNKotomi Nagahashi
Kotomi Nagahashi
KTKatsuhiro Takano
Katsuhiro Takano
KSKatsue Suzuki-Inoue
Katsue Suzuki-Inoue
NKNaohiro Kanayama
Naohiro Kanayama
KUKazuo Umemura
Kazuo Umemura
TITakayuki Iwaki
Takayuki Iwaki
Serpinopathy is characterised as abnormal accumulation of serine protease inhibitors (SERPINs) in cells and results in clinical symptoms owing to lack of SERPIN function or excessive accumulation of abnormal SERPIN. We recently identified a patient with functional deficiency of plasminogen activator inhibitor-1 (PAI-1), a member of the SERPIN superfamily. The patient exhibited life-threatening bleeding tendencies, which have also been observed in patients with a complete deficiency in PAI-1. Sequence analysis revealed a homozygous singlenucleotide substitution from guanine to cytosine at exon 9, which changed amino acid residue 397 from glycine to arginine (c.1189G>C; p.Gly397Arg). This glycine was located in strand 5B and was well conserved in other serpins. The mutant PAI-1 was polymerised in the cells, interfering with PAI-1 secretion. The corresponding mutations in SERPINC1 (anti-thrombin III) at position 456 (Gly456Arg) and SERPINI1 (neuroserpin) at position 392 (Gly392Glu) caused an anti-thrombin deficiency and severe dementia due to intracellular retention of the polymers. Glycine is the smallest amino acid, and these mutated amino acids were larger and charged. To determine which factors were important, further mutagenesis of PAI-1 was performed. Although the G397A, C, I, L, S, T, and V were secreted, the G397D, E, F, H, K, M, N, P, Q, W, and Y were not secreted. The results revealed that the size was likely triggered by the polymerisation of SEPRINs at this position. Structural analyses of this mutated PAI-1 would be useful to develop a novel PAI-1 inhibitor, which may be applicable in the context of several pathological states.

18 September 2006 in The Journal of Pathology
Verified
Journal Article
Closed access
PDF file
DCDiana Cruz
Diana Cruz
TITakayuki Iwaki
Takayuki Iwaki
VPVa Ploplis
Va Ploplis
FCFrancis J. Castellino
Francis J. Castellino

1 April 2012 in Thrombosis Research
Verified
Journal Article
Closed access
TITakayuki Iwaki
Takayuki Iwaki
KNKotomi Nagahashi
Kotomi Nagahashi
TKTakao Kobayashi
Takao Kobayashi
KUKazuo Umemura
Kazuo Umemura
TTToshihiko Terao
Toshihiko Terao
NKNaohiro Kanayama
Naohiro Kanayama